Table 1 Current phase II/III trials assessing EGFR inhibitors in combination with radiation (RT) locally advanced non-metastatic stage IV squamous-cell cancer of the head and neck
Trial | Protocol ID | EGFR inhibitor | Status | Comments |
|---|---|---|---|---|
Phase III | RTOG-0522 | Cetuximab | Active | Concurrent chemoRT +/- C225 |
Phase II | ECOG-E3303 | Cetuximab | Active | Concurrent chemoRT + C225, followed C225 maintenance |
Phase II | RTOG-0234 | Cetuximab | Active | Surgery followed by adjuvant chemoRT (cisplatin vs. docetaxel) + C225 |
Phase II | NCT00140556 | Erlotinib | Active | Concurrent chemoRT + erlotinib + bevacizumab |
Phase II | NCT00226239 | Cetuximab | Active | Induction chemotherapy with docetaxel/cisplatin + C225 followed by RT/cisplatin + C225 |
Phase II | NCT00193284 | Gefitinib | Active | Induction chemotherapy with docetaxel/carboplatin/5-FU + gefitinib followed by RT/gefitinib +/- docetaxel |